[1] |
Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP[J]. J Dermatol, 2018,45(11):1235⁃1270. doi: 10.1111/1346⁃8138.14523.
|
[2] |
Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis ⁃ a model disease for specific targeted immunotherapy, systematic review[J]. Exp Dermatol, 2018,27(10):1067⁃1077. doi: 10.1111/exd.13699.
|
[3] |
Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52⁃week analysis from phase III open⁃label multicenter Japanese study[J]. J Dermatol, 2016,43(9):1011⁃1017. doi: 10.1111/1346⁃ 8138.13306.
|
[4] |
Cordoro KM, Ucmak D, Hitraya⁃Low M, et al. Response to interleukin (IL)⁃17 inhibition in an adolescent with severe manifestations of IL⁃36 receptor antagonist deficiency (DITRA) [J]. JAMA Dermatol, 2017,153(1):106⁃108. doi: 10.1001/jamadermatol.2016.3490.
|
[5] |
Molho⁃Pessach V, Alyan R, Gordon D, et al. Secukinumab for the treatment of deficiency of interleukin 36 receptor antagonist in an adolescent[J]. JAMA Dermatol, 2017,153(5):473⁃475. doi: 10.1001/jamadermatol.2016.5705.
|
[6] |
Ho PH, Tsai TF. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: a case report and review of published work[J]. J Dermatol, 2018,45(11):1353⁃1356. doi: 10.1111/1346⁃8138.14636.
|
[7] |
Köstner K, Prelog M, Almanzar G, et al. Successful use of secukinumab in a 4⁃year⁃old patient with deficiency of interleukin⁃36 antagonist[J]. Rheumatology (Oxford), 2018,57(5):936⁃938. doi: 10.1093/rheumatology/kex510.
|
[8] |
Nishida M, Takeichi T, Kono M, et al. Successful secukinumab treatment of recalcitrant juvenile generalized pustular psoriasis[J]. J Dermatol, 2020,47(3):e77⁃e78. doi: 10.1111/1346⁃8138. 15228.
|
[9] |
Wilsmann⁃Theis D, Schnell LM, Ralser⁃Isselstein V, et al. Successful treatment with interleukin⁃17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations[J]. J Dermatol, 2018,45(7):850⁃854. doi: 10.1111/1346⁃8138.14318.
|